DIM
NXTC icon

DC Investments Management’s NextCure NXTC Stock Holding History

DC Investments Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,513
Closed -$452K – 333
2019
Q2 		$452K Buy
+2,513
New +$522K 0.25% 173

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DC Investments Management's NXTC Position: Q3 2019 in Review

DC Investments Management sold out of NextCure (NXTC) in Q3 2019, closing a stake of 2,513 shares — an estimated $452K sold.

DC Investments Management first reported a position in NXTC in Q2 2019 and held it in 1 quarter. The position peaked at $452K in Q2 2019. 52 funds tracked by Wall St. Rank hold NXTC as of Q3 2019.

  • DC Investments Management reported no remaining NextCure position as of Q3 2019 after selling out during the quarter.
  • DC Investments Management sold 2,513 NextCure shares in Q3 2019, an estimated $452K.
  • DC Investments Management first reported a position in NextCure in Q2 2019 and held it in 1 quarter.
  • DC Investments Management's NextCure position peaked at $452K in Q2 2019.
  • 52 funds tracked by Wall St. Rank held NextCure as of Q3 2019.

Based on DC Investments Management's 13F filing for Q3 2019, filed 5 Nov 2019.